Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice

Clinical Cancer Research

Volumn 3, Issue 5, 1997, Pages 653-659

  Kurebayashi, Junichi ^a   Nukatsuka, Mamoru ^b   Fujioka, Akio ^b   Saito, Hitoshi ^b   Takeda, Setsuo ^b   Unemi, Norio ^b   Fukumori, Hiroyuki ^b   Kurosumi, Masafumi ^c   Sonoo, Hiroshi ^a   Dickson, Robert B ^d  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; COLLAGENASE; METALLOPROTEINASE INHIBITOR; TEGAFUR; URACIL;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANIMALS; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOPLASM METASTASIS; TEGAFUR; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; URACIL;

EID: 0030921381     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women (Part 1). Lancet, 339: 1-15, 1992.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women (Part 2). Lancet, 339: 71-85, 1992.
3. Perren, T. J. Adjuvant therapy for operable breast cancer; more answers, new questions. Br. J. Cancer, 71: 1142-1144, 1995.
4. Sledge, G. W., Jr., Qulali, M., Goulet, R., Bone, E. A., and Fife, R. Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst., 87: 1546-1550, 1995.
5. Price, J. E., Polyzos, A., Zhang, R. D., and Daniels, L. M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res., 50: 717-721, 1990.
6. McLeskey, S. W., Kurebayashi, J., Honig, S. F., Ziebel, J., Lippman, M. E., and Kern, F. G. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res., 53: 2168-2177, 1993.
7. Kurebayashi, J., McLeskey, S. W., Johnson, M. D., Lippman, M. E., Dickson, R. B., and Kern, F. G. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and lacZ. Cancer Res., 53: 2178-2187, 1993.
8. Kurebayashi, J., Kurosumi, M., Dickson, R. B., and Sonoo, H. Angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) inhibits tumor angiogenesis, growth and spontaneous metastasis of MKL-4 human breast cancer cells in female athymic nude mice. Breast Cancer, 1: 109-115, 1994.
9. Toide, H., Akiyoshi, H., Minato, Y., Okuda, H., and Fujii, S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann, 68: 553-560, 1977.
10. Fujii, S., Ikenaka, K., Fukushima, M., and Shirasaka, T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann, 69: 763-772, 1978.
11. Taguchi, T., Nakao, Y., Fujii, S., and Shirasaka, T. Determination of 5-fluorouracil levels in tumors, blood and other tissues. Cancer Chemother., 5: 1167-1172, 1978.
12. Fujii, S., Kitano, S., Ikenaka, K., and Shirasaka, T. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann, 70: 209-214, 1979.
13. Ota, K., Taguchi, T., and Kimura, K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333-338, 1988.
14. Kurihara, M. Clinical experience with UFT in Japan. Adv. Exp. Med. Biol., 339: 243-251, 1993.
15. Malik, S. T. A., Talbot, D., Clarke, P. I., Osborne, R., Reznek, R., Wringley, P. F. M., and Slevin, M. L. Phase II trial of UFT in advanced colorectal and gastric cancer. Br. J. Cancer, 62: 1023-1025, 1990.
16. Ho, D. H., Civington, W. P., Pazdur, R., Brown N. S., Kuritani, J., Newman, R. A., Raber M. N., and Krakoff, I. H. Clinical pharmacology of combined oral uracil and ftorafur. Drug Metab. Dispos., 20: 936-940, 1992.
17. Gonzalezbaron, M., Feliu, J., Ordonez, A., Colmenarejo, A., Espinosa, E., Zamora, P., Gandara, I. D., and Jalon, J. I. Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal. Anticancer Res., 13: 759-762, 1993.
18. Daniels, M., Diaz-Rubio, E., Guillem, V., Montero, J. M., Garcia-Conde, J., Estape, J., Martin M., Herranz, C., Ordenez, A., and Galan, A. Phase II trial of UFT activity in pretreated breast cancer patients. Jpn. J. Clin. Oncol., 23: 363-365, 1993.
19. Pazdur, R., Lassere, Y., Rhodes, V., Ajani, J. A., Sugarman, S. M., Patt, Y. Z., Jones, D. V., Jr., Markowitz, A. B., Abbruzzese, J. L., Bready, B., and Levin, B. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994.
20. Sanchiz, F., and Milla, A. Tegafur.uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn. J. Clin. Oncol., 24: 322-326, 1994.
21. Saltz, L. B., Leichman, C. G., Young, C. W., Muggia, F. M., Conti, J. A., Spiess, T., Jeffers, S., and Leichman, L. P. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. Cancer (Phila.), 75: 782-785, 1995.
22. Cao, S., Frank, C., Shirasaka, T., and Rustum, Y. M. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin. Cancer Res., 1: 839-845, 1995.
23. Puzdar, R., Covingotn, W. P., Brown, N. S., Lassere, Y., Diaz-Canton, E., and Ho, D. H. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU) (Abstract). Proc. Am. Soc. Clin. Oncol., 15: 474, 1996.
24. Maehara, Y., Watanabe, A., Kakeji, Y., Baba, H., Kohnoe, S., and Sugimachi, K. Postgastrectomy prescription of mitomycin C and UFT for patients with stage IV gastric carcinoma. Am. J. Surg., 160: 242-244, 1990.
25. The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur. J. Surg. Oncol., 21: 69-77, 1995.
26. Arima, S., Ohsato, K., Hisatsugu, T., and Shimura, H. Multicentre randomised study of adjuvant chemotherapy with mitomycin C and tegafur or tegafur-uracil in gastric cancer. Eur. J. Surg., 160: 227-232 1994.
27. Wada, H., Hitomi, S., and Teramatsu, T. Postoperative non-small cell lung cancer: a prospective randomized trial of cisplatin (P)-vindesine (VDS)-UFT vs UFT alone vs control (Abstract). Proc. Am. Soc. Clin. Oncol., 13: 328, 1994.
28. Schatten, W. E. An experimental study of postoperative tumor metastases. I. Growth of pulmonary metastases following total removal of primary leg tumor. Cancer (Phila.), 11: 455-459, 1958.
29. DeWys, W. D. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res., 32: 374-379, 1972.
30. Gorelik, E., Segal, S., and Feldman, M. Growth of a local tumor exerts a specific inhibitory effect on progression of lung metastases. Int. J. Cancer, 21: 617-625, 1978.
31. Fisher, B., Gunduz, N., and Saffer, E. A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res., 43: 1488-1492, 1983.
32. Fisher, B., Gunduz, N., Coyle, J., Rudock, C., and Saffer, E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res., 49: 1996-2001, 1989.
33. O'Reilly, M. S., Rosenthal, R., Sage, E. H., Smith, S., Holmgren, L., Moses, M., Shing, Y., and Folkman, J. The suppression of tumor metastases by a primary tumor. Surg. Forum, 44: 474-476, 1993.
34. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
35. Holmgren, L., O'Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.
36. Yonemura, Y., Sawa, T., and Kinoshoshita, K. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J. Surg., 17: 256-261, 1993.
37. Hayakawa, M., Morise, K., Chin, K., Sugihara, M., Morooka, Y., Maeda, H., Hattori, T., and Saito, H. Combination chemotherapy with tegafur.uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer. Jpn. J. Clin. Oncol., 24: 282-288, 1994.
38. Kurebayashi, J., and Sonoo, H. Antiproliferative and antimetastatic effects of UFT on MKL-4 human breast cancer cells transplanted into nude mice. Jpn. J. Cancer Chemother., 22: 665-670, 1995.
39. Kono, A., Hara, Y., and Masmshima, Y. Enzymatic formation of 5-fluorouracil from 1-(tetrahydro-2-furanyl)-5-fluorouracil (tegafur) in human tumor tissues. Chem. & Pharm. Bull. (Tokyo), 29: 1486-1488, 1981.
40. Sumizawa, T., Furukawa, T., Haraguchi, M., Yoshimura, A., Takeyasu, A., Ishizawa, M., Yamada, Y., and Akiyama, S. Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J. Biochem., 114: 9-14, 1993.
41. Yoshimura, A., Kuwazuru, Y., Furukawa, T., Yoshida, H., Yamada, K., and Akiyama, S. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim. Biophys. Acta, 1034: 107-113, 1990.